3GOLD Executive Committee[DB/OL]. Guidelines: Global Strategy for Diagnosis, Management, and Prevention of COPD,November 2006 [ 2006-11-18 ]. http://www.goldcopd.com/Guidelineitem. asp? 11 =2&12 = 1&intId =989.
4Celli BR, MacNee W, Committee members. Standard for the diagnosis and treatment of patients with COPD : a summary of the ATS/ERS position paper. Eur Respir J, 2004,23:932-946.
5Celli BR, Cote CG, Matin JM, et al. The body mass index,airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med, 2004,350 : 1005-1012.
6Di Marco F, Verga M, Santus P. Effect of formoterol, tiotropium,and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir Med,2006,100: 1925-1932.
7Turner MO, Patel A, Ginsburg S, et al. Bronchodilator delivery in acute airflow obstruction. A meta-analysis. Arch Intern Med,1997,157: 1736-1744.
8Turner MO, Gafnl A, Swan D, et al. A review and economic evaluation of bronchodilator delivery methods in hospitalized patients. Arch Intern Med, 1996,156:2113-2118.
9Levitt MA, Gambrioli EF, Fink JB. Comparative trial of continuous nebulization versus metered-dose inhaler in the treatment of acute bronchospasm. Ann Emerg Med, 1995,26:273-277.
10Gartlehner G, Hansen BA, Carson SS, et al. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. J Faro Pract, 2006,55:756.
